4D Molecular TherapeuticsFDMT
FDMT
About: 4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
Employees: 227
0
Funds holding %
of 7,433 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
16% more call options, than puts
Call options by funds: $171K | Put options by funds: $147K
7% more capital invested
Capital invested by funds: $141M [Q1] → $151M (+$9.63M) [Q2]
3% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 40
6% less funds holding
Funds holding: 124 [Q1] → 117 (-7) [Q2]
6.14% less ownership
Funds ownership: 93.06% [Q1] → 86.92% (-6.14%) [Q2]
24% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 21
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$25
283%
upside
Avg. target
$32
382%
upside
High target
$38
482%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Roth Capital Salveen Richter | 482%upside $38 | Buy Maintained | 12 Aug 2025 |
Chardan Capital Geulah Livshits | 283%upside $25 | Buy Maintained | 12 Aug 2025 |
Financial journalist opinion
Based on 8 articles about FDMT published over the past 30 days
Neutral
GlobeNewsWire
1 day ago
4DMT to Participate in Upcoming Investor Conferences
EMERYVILLE, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will participate in fireside chats at upcoming investor conferences in September. Members of the management team will also be available for one-on-one meetings.
Neutral
GlobeNewsWire
1 week ago
4DMT Announces New Employment Inducement Grants
EMERYVILLE, Calif., Aug. 15, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on August 12, 2025, the compensation committee of the Company's board of directors granted three new non-executive employees 58,900 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company's 2025 Employment Inducement Award Plan, which was approved by the Company's board of directors in February 2025 under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.
Negative
Zacks Investment Research
2 weeks ago
4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Misses Revenue Estimates
4D Molecular Therapeutics, Inc. (FDMT) came out with a quarterly loss of $0.98 per share versus the Zacks Consensus Estimate of a loss of $0.88. This compares to a loss of $0.63 per share a year ago.
Neutral
GlobeNewsWire
2 weeks ago
4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today reported Q2 2025 financial results, provided operational highlights and outlined expected upcoming milestones.
Neutral
GlobeNewsWire
2 weeks ago
4DMT to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
EMERYVILLE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will participate in a fireside chat at the H.C.
Negative
Finbold
3 weeks ago
These 3 health tech stocks spiked 37% in a day; Time to buy?
While the broader stock market suffered steep losses on Friday amid trade policy shifts and troubling economic data, select health technology equities stood out.
Positive
Benzinga
3 weeks ago
4D Molecular Therapeutics Rallies On Heels Of Diabetes-Related Vision Study
Shares of 4D Molecular Therapeutics FDMT are currently up over 20.6% after the company released positive results from its Spectra trial.
Neutral
GlobeNewsWire
3 weeks ago
4DMT Presents Positive 60-Week Results from 4D-150 SPECTRA Clinical Trial in DME and Regulatory Update
EMERYVILLE, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced positive results from the SPECTRA clinical trial evaluating 4D-150 in patients with diabetic macular edema (DME), and alignment with the European Medicines Agency (EMA) on a registrational pathway for 4D-150 in DME. The data, which included both the 52-week primary endpoint and 60-week analyses, were presented by David Almeida, M.D., MBA, Ph.D., Erie Retina Research in an oral presentation titled “Interim Results from the SPECTRA Phase 2a Clinical Trial Evaluating Intravitreal 4D-150 in Adults with Diabetic Macular Edema” at the 43rd Annual American Society of Retina Specialists (ASRS) Scientific Meeting.
Neutral
GlobeNewsWire
1 month ago
4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina Specialists
EMERYVILLE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced podium presentations at the 43rd Annual Scientific Meeting of the American Society of Retina Specialists (ASRS) being held in Long Beach, CA, from July 30 – August 2, 2025.
Neutral
GlobeNewsWire
1 month ago
4DMT Announces New Employment Inducement Grants
EMERYVILLE, Calif., July 11, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on July 8, 2025, the compensation committee of the Company's board of directors granted one new non-executive employee 4,600 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company's 2025 Employment Inducement Award Plan, which was approved by the Company's board of directors in February 2025 under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.
Charts implemented using Lightweight Charts™